Japanese Biotech Reports New, Safer Way To Create iPS Cells
This article was originally published in PharmAsia News
Executive SummaryJapan's Dnavec, a biotech start-up company, says it found a way to create induced pluripotent stem cells by using a virus whose cells are kept intact. Dnavec's researchers said their new method goes a long way to lower the risk of the cells becoming cancerous. The work, soon to be published in a science journal, is considered significant because with the team's method the genes carried by the virus disappear after the iPS cells are created, making it far less likely they would grow out of control and form a tumor after being transplanted. (Click here for more - a subscription may be required
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.